drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody
drug_description
Anti–folate receptor alpha (FRα) IgG monoclonal antibody serving as the targeting moiety of MORAb-202 to bind FRα and enable receptor-mediated endocytosis.
nci_thesaurus_concept_id
C61503
nci_thesaurus_preferred_term
Farletuzumab
nci_thesaurus_definition
A humanized, immunoglobulin G1 monoclonal antibody with potential antitumor activity. Farletuzumab specifically targets at glycoprotein 3 (GP-3), a cell surface antigen that is overexpressed on many epithelial-derived cancer cells. Upon binding to the GP-3 antigen, farletuzumab triggers a host immune response against GP-3 expressing cells resulting in cell lysis.
drug_mesh_term
Farletuzumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized IgG1 monoclonal antibody targeting folate receptor alpha (FR-alpha) overexpressed on epithelial cancers; binding elicits Fc-mediated ADCC and CDC to kill FR-alpha–positive cells and facilitates receptor-mediated internalization (serving as the targeting moiety for ADCs such as MORAb-202).
drug_name
Farletuzumab
nct_id_drug_ref
NCT05613088